US 12,295,969 B2
Pharmaceutical composition comprising cyclodextrin complexes of anethole trithione or derivatives thereof
Nicolas Pineau, Carbon-Blanc (FR); El Mustapha Belgsir, Poitiers (FR); Frédéric Turpin, Tours (FR); Anne-Gaëlle Fournial, La Madeleine (FR); Aswin Dereymaker, Halle (BE); Natascha Audoore, Merelbeke (BE); and Ine De Cock, Ghent (BE)
Assigned to Frédéric Marin, Paris (FR)
Appl. No. 17/273,928
Filed by Frédéric Marin, Paris (FR)
PCT Filed Sep. 6, 2019, PCT No. PCT/EP2019/073873
§ 371(c)(1), (2) Date Mar. 5, 2021,
PCT Pub. No. WO2020/049166, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/727,691, filed on Sep. 6, 2018.
Claims priority of application No. 18306172 (EP), filed on Sep. 6, 2018.
Prior Publication US 2021/0308173 A1, Oct. 7, 2021
Int. Cl. A61K 31/737 (2006.01); A61K 9/19 (2006.01); A61K 31/385 (2006.01); A61K 31/423 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01)
CPC A61K 31/737 (2013.01) [A61K 9/19 (2013.01); A61K 31/385 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01)] 14 Claims
 
1. A composition comprising sulfobutyl ether-beta-cyclodextrin and a compound of formula (I);

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable tautomer, salt or solvate thereof wherein:
X is S, O or NHOH;
Y is CH, C or N;
R1, R2, R4 and R5 each independently is hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;
R3 is hydroxy or methoxy; or R3 and R2 together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein —R3—R2— is -A—CR6═B— or —B═CR6-A-; wherein:
A is O, S or NR7; wherein R7 is hydrogen, C1-C8 alkyl or alkyloxycarbonyl;
B is CH or N; and
R6 is hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;
wherein the molar ratio of the sulfobutyl ether-beta-cyclodextrin to the compound of formula (I) ranges from 10 to 400.